Five Prime Therapeutics (FPRX) Misses Q3 EPS by 30c

Five Prime Therapeutics (NASDAQ: FPRX) reported Q3 EPS of ($1.54), $0.30 worse than the analyst estimate of ($1.24).

For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Ubiquiti (UI) Tops Q4 EPS by 25c, Beats on Revenue
• S&P 500 may pull back before midterms, but Citi says buy the dip